CYTK Stock Analysis: Buy, Sell, or Hold?
CYTK - Cytokinetics Inc.
$80.32
1.14 (1.45%)
▲
5d:
+12.52%
30d:
+2.89%
90d:
+31.77%
BUY
MODERATE Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Smart Money Accumulation
None View Scanner →
Strength: 6.1/10
Get Alerted When CYTK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CYTK shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: CYTK shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CYTK is currently trading at $80.31, which is considered extended relative to its 30-day fair value range of $70.53 to $78.04.
Technical Outlook: Technically, CYTK is in a strong uptrend. The price is approaching resistance at $80.80. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CYTK has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $104.70 (+32.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CYTK is in a strong uptrend. The price is approaching resistance at $80.80. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CYTK has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $104.70 (+32.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$70.53 -
$78.04
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 32.2% below Wall St target ($104.70)
Trading Range Analysis
30-Day Trading Range
$70.53 -
$78.04
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$66.63
Resistance Level
$80.80
Current Trend
Strong Uptrend
Technical data as of
Jun 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-16.65
Wall Street Target
$104.70
(+32.2%)
Revenue Growth (YoY)
1125.8%
Share & Embed Analysis
Last updated: June 23, 2026 10:13 AM ET
Data refreshes hourly during market hours. Next update: 11:13 AM
Data refreshes hourly during market hours. Next update: 11:13 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CYTK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
19
Sells
Net
INSIDERS SELLING
Recent Transactions
Fady Ibraham Malik
SELL
3500 shares
2026-04-21
Robert I Blum
SELL
7500 shares
2026-04-15
Andrew Callos
SELL
7449 shares
2026-04-15
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 67 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$105 | 66 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 59 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 67 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 64 BUY |
Advanced CYTK Option Strategies
Professional options setups generated by AI based on today's CYTK price and gamma walls.
